WuXi STA, a subsidiary of WuXi AppTec, is a leading CRDMO providing integrated CMC services including both API and drug product for oligonucleotides, peptides and complex conjugates from discovery to development and commercial manufacturing. We have 12 R&D and manufacturing sites across Asia, North America and Europe.

Our CRDMO platform for oligonucleotides and peptides involves their novel monomers, payloads and linkers, and complex conjugates. Coupled with injectable formulation development and manufacturing services, including Lipid Nano Particle technology (LNP), we enable global partners to accelerate new therapeutics for patients worldwide.